TEL AVIV, Israel, July 30, 2014 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. ("BioBlast"), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today the pricing of its initial public offering of 3,200,000 ordinary shares at an initial public offering price of $11.00 per share. The gross proceeds to BioBlast from the initial public offering are expected to be $35,200,000, before underwriting discounts and commissions and other estimated offering expenses. BioBlast has granted the underwriters a 30-day option to purchase up to 480,000 additional ordinary shares to cover over-allotments, if any, at the public offering price less the underwriting discount. The ordinary shares have been approved for listing on The NASDAQ Global Market under the ticker symbol "ORPN" and are expected to begin trading on July 31, 2014. The offering is expected to close on August 5, 2014, subject to customary closing conditions.
Oppenheimer & Co. and Roth Capital Partners are acting as joint book-running managers for the offering. BTIG is acting as co-manager.
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission on July 30, 2014. This offering is being made only by means of a prospectus, copies of which can be obtained by contacting Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8563, or by email at EquityProspectus@opco.com, or Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, California 92660, or by telephone at (800) 678-9147, or by email at email@example.com, or by accessing the SEC's website, www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Bio Blast Pharma Ltd.'s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Bio Blast Pharma could differ materially from those described in or implied by the statements in this press release, including, but not limited to, our initial public offering, market conditions, the satisfaction of conditions precedent for the closing of the offering and the anticipated closing date of our initial public offering. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Bio Blast Pharma's registration statement on Form F-1 filed with the Securities and Exchange Commission ("SEC") and in any subsequent filings with the SEC. Except as otherwise required by law, Bio Blast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
U.S. Investor Contact: Michael Rice Founding Partner LifeSci Advisors, LLC (646) 597-6979